Cargando…

Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation

BACKGROUND: Tolerance seriously impedes the application of morphine in clinical medicine. Thus, it is necessary to investigate the exact mechanisms and efficient treatment. Microglial activation and neuroinflammation in the spinal cord are thought to play pivotal roles on the genesis and maintaining...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yinbing, Sun, Xiaodi, Jiang, Lai, Hu, Liang, Kong, Hong, Han, Yuan, Qian, Cheng, Song, Chao, Qian, Yanning, Liu, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114746/
https://www.ncbi.nlm.nih.gov/pubmed/27855689
http://dx.doi.org/10.1186/s12974-016-0754-9
_version_ 1782468397701791744
author Pan, Yinbing
Sun, Xiaodi
Jiang, Lai
Hu, Liang
Kong, Hong
Han, Yuan
Qian, Cheng
Song, Chao
Qian, Yanning
Liu, Wentao
author_facet Pan, Yinbing
Sun, Xiaodi
Jiang, Lai
Hu, Liang
Kong, Hong
Han, Yuan
Qian, Cheng
Song, Chao
Qian, Yanning
Liu, Wentao
author_sort Pan, Yinbing
collection PubMed
description BACKGROUND: Tolerance seriously impedes the application of morphine in clinical medicine. Thus, it is necessary to investigate the exact mechanisms and efficient treatment. Microglial activation and neuroinflammation in the spinal cord are thought to play pivotal roles on the genesis and maintaining of morphine tolerance. Activation of adenosine monophosphate-activated kinase (AMPK) has been associated with the inhibition of inflammatory nociception. Metformin, a biguanide class of antidiabetic drugs and activator of AMPK, has a potential anti-inflammatory effect. The present study evaluated the effects and potential mechanisms of metformin in inhibiting microglial activation and alleviating the antinociceptive tolerance of morphine. METHODS: The microglial cell line BV-2 cells and mouse brain-derived endothelial cell line bEnd3 cells were used. Cytokine expression was measured using quantitative polymerase chain reaction. Cell signaling was assayed by western blot and immunohistochemistry. The antinociception and morphine tolerance were assessed in CD-1 mice using tail-flick tests. RESULTS: We found that morphine-activated BV-2 cells, including the upregulation of p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation, pro-inflammatory cytokines, and Toll-like receptor-4 (TLR-4) mRNA expression, which was inhibited by metformin. Metformin suppressed morphine-induced BV-2 cells activation through increasing AMPK phosphorylation, which was reversed by the AMPK inhibitor compound C. Additionally, in BV-2 cells, morphine did not affect the cell viability and the mRNA expression of anti-inflammatory cytokines. In bEnd3 cells, morphine did not affect the mRNA expression of interleukin-1β (IL-1β), but increased IL-6 and tumor necrosis factor-α (TNF-α) mRNA expression; the effect was inhibited by metformin. Morphine also did not affect the mRNA expression of TLR-4 and chemokine ligand 2 (CCL2). Furthermore, systemic administration of metformin significantly blocked morphine-induced microglial activation in the spinal cord and then attenuated the development of chronic morphine tolerance in mice. CONCLUSIONS: Metformin significantly attenuated morphine antinociceptive tolerance by suppressing morphine-induced microglial activation through increasing AMPK phosphorylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-016-0754-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5114746
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51147462016-11-25 Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation Pan, Yinbing Sun, Xiaodi Jiang, Lai Hu, Liang Kong, Hong Han, Yuan Qian, Cheng Song, Chao Qian, Yanning Liu, Wentao J Neuroinflammation Research BACKGROUND: Tolerance seriously impedes the application of morphine in clinical medicine. Thus, it is necessary to investigate the exact mechanisms and efficient treatment. Microglial activation and neuroinflammation in the spinal cord are thought to play pivotal roles on the genesis and maintaining of morphine tolerance. Activation of adenosine monophosphate-activated kinase (AMPK) has been associated with the inhibition of inflammatory nociception. Metformin, a biguanide class of antidiabetic drugs and activator of AMPK, has a potential anti-inflammatory effect. The present study evaluated the effects and potential mechanisms of metformin in inhibiting microglial activation and alleviating the antinociceptive tolerance of morphine. METHODS: The microglial cell line BV-2 cells and mouse brain-derived endothelial cell line bEnd3 cells were used. Cytokine expression was measured using quantitative polymerase chain reaction. Cell signaling was assayed by western blot and immunohistochemistry. The antinociception and morphine tolerance were assessed in CD-1 mice using tail-flick tests. RESULTS: We found that morphine-activated BV-2 cells, including the upregulation of p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation, pro-inflammatory cytokines, and Toll-like receptor-4 (TLR-4) mRNA expression, which was inhibited by metformin. Metformin suppressed morphine-induced BV-2 cells activation through increasing AMPK phosphorylation, which was reversed by the AMPK inhibitor compound C. Additionally, in BV-2 cells, morphine did not affect the cell viability and the mRNA expression of anti-inflammatory cytokines. In bEnd3 cells, morphine did not affect the mRNA expression of interleukin-1β (IL-1β), but increased IL-6 and tumor necrosis factor-α (TNF-α) mRNA expression; the effect was inhibited by metformin. Morphine also did not affect the mRNA expression of TLR-4 and chemokine ligand 2 (CCL2). Furthermore, systemic administration of metformin significantly blocked morphine-induced microglial activation in the spinal cord and then attenuated the development of chronic morphine tolerance in mice. CONCLUSIONS: Metformin significantly attenuated morphine antinociceptive tolerance by suppressing morphine-induced microglial activation through increasing AMPK phosphorylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-016-0754-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-17 /pmc/articles/PMC5114746/ /pubmed/27855689 http://dx.doi.org/10.1186/s12974-016-0754-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pan, Yinbing
Sun, Xiaodi
Jiang, Lai
Hu, Liang
Kong, Hong
Han, Yuan
Qian, Cheng
Song, Chao
Qian, Yanning
Liu, Wentao
Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title_full Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title_fullStr Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title_full_unstemmed Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title_short Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
title_sort metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114746/
https://www.ncbi.nlm.nih.gov/pubmed/27855689
http://dx.doi.org/10.1186/s12974-016-0754-9
work_keys_str_mv AT panyinbing metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT sunxiaodi metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT jianglai metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT huliang metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT konghong metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT hanyuan metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT qiancheng metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT songchao metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT qianyanning metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation
AT liuwentao metforminreducesmorphinetolerancebyinhibitingmicroglialmediatedneuroinflammation